Answer
Use should be avoided in end-stage renal disease requiring haemodialysis because evidence is unavailable. Severe liver impairment requires caution because netupitant exposure may be increased.
Sources for this answer
- Akynzeo 300mg/0.5mg hard capsules — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.